Objective: Currently accepted for the treatment of advanced renal cancer, sunitinib malate is a small molecule inhibitor of the VEGFR family, with ability to regulate tumor growth, progression, angiogenesis and metastasis. Several reports have suggested that encouraging effects can be achieved by combining COX-2 inhibitors with anticancer agents. The goal of this work was to evaluate the effects of sunitinib malate and meloxicam isolated and combined on three human bladder cancer cell lines. Method: T24, 5637 and HT1376 cells were treated with several concentrations of sunitinib malate and meloxicam, as single agents or in combined schedule. Their influence on cell proliferation was determined by MTT method after 72 h of treatment. Control samples were processed in the same way as treated samples but in drug-free medium. Absorbance values of each well were read at 492 nm using an ELISA plate reader. Results: A reduction in cell proliferation rate was observed when all cell lines were treated either with sunitinib malate or meloxicam isolated. Simultaneous exposure to both agents enhances the inhibition of cell proliferation. Statistical significances were obtained when treatment groups were compared with control group. Conclusion: These results suggest a potential clinical application of sunitinib malate in combination with meloxicam on bladder cancer.